Constructive news tone
News Sentiment
GANX sentiment intelligence
Gain Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
64
Constructive news tone
51 relevant articles
Constructive headlines are not being rewarded by price, which raises a rejection flag.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-5.8% over one week, +7.1% over four weeks, trend inactive, and below fair value.
Gain Therapeutics (GANX) Q1 2026 earnings summary
Market Reaction
Positive news being faded
Constructive headlines are not being rewarded by price, which raises a rejection flag.
Primary event
Market update
75/100 classification
One-week reaction
-5.8%
Price reacting lower
Trend fit
Trend inactive
7.1% over four weeks
Fair value
-24.3%
Below fair value
Sentiment-trend disagreement
Value support
Sentiment Mix
Positive, neutral, negative
Positive
32
Neutral
15
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
Gain Therapeutics (GANX) Q1 2026 earnings summary
Gain Therapeutics (GANX) reported a Q1 2026 net loss of $5.6 million, or $0.13 per share, with increased R&D and G&A expenses due primarily to the GT-02287 program for Parkinson's disease. The company anticipates IND clearance for GT-02287 in Q2 2026 and Phase 2 trial initiation
- Tone
- Negative 36/100
- Event
- Earnings
- Published
- 13 Jul 2026 05:10
- Source
- Quartr
Quartr
Direct company coverage
Gain Therapeutics (GANX) Q4 2025 earnings summary
Gain Therapeutics (GANX) reported its Q4 2025 earnings, highlighting advancements in its Parkinson's disease candidate, GT-02287, which showed promising Phase 1b data and disease-modifying potential. The company saw a decrease in both R&D and G&A expenses, leading to a slightly r
- Tone
- Positive 74/100
- Event
- Earnings
- Published
- 12 Jul 2026 16:40
- Source
- Quartr
Quartr
Direct company coverage
Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary
This article summarizes Gain Therapeutics' presentation at the 38th Annual Roth Conference, focusing on their therapeutic approach for Parkinson's disease. The company uses its Magellan platform to develop GT-02287, a drug designed to stabilize the GCase protein and modify the di
- Tone
- Positive 91/100
- Event
- Market update
- Published
- 12 Jul 2026 11:39
- Source
- Quartr
Parkinson's News Today
Direct company coverage
With new FDA green light for developer, Parkinson’s clinical trial to launch soon
The FDA has approved Gain Therapeutics to begin a clinical trial for its oral Parkinson's therapy, GT-02287. This therapy aims to prevent toxic protein clumps from forming in the brain by restoring the activity of the GCase enzyme. Previous studies showed GT-02287 to be safe and
- Tone
- Positive 86/100
- Event
- Market update
- Published
- 07 Jul 2026 04:09
- Source
- Parkinson's News Today
TradingView
Direct company coverage
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX
The article provides a financial metric for Gain Therapeutics, Inc. (NASDAQ: GANX), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. It appears to be a stub or partial financial data point from TradingView, indicating a period value, and cha
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 15:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Gain Therapeutics, Inc. – NASDAQ:GANX
This article provides the enterprise value to revenue forward for Gain Therapeutics, Inc. (NASDAQ: GANX). The financial data is available on TradingView, which also provides additional market and company information.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 07:40
- Source
- TradingView
Moomoo
Direct company coverage
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7
Maxim Group has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its price target at $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 03 Jul 2026 14:10
- Source
- Moomoo
BioBuzz
Direct company coverage
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing it to advance into Phase 2 clinical development for Parkinson’s disease in the U.S. This decision follows positive Phase 1 results demonstrating favorable sa
- Tone
- Positive 73/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 03:39
- Source
- BioBuzz
Investing.com
Direct company coverage
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval
H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Gain Therapeutics (NASDAQ:GANX) after the FDA authorized the company's Investigational New Drug application for GT-02287. This FDA decision allows Gain Therapeutics to initiate Phase 2 clinical assessment i
- Tone
- Positive 90/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 02:11
- Source
- Investing.com
Moomoo
Direct company coverage
Gain Therapeutics Is Maintained at Buy by BTIG
BTIG has reiterated its Buy rating for Gain Therapeutics (NASDAQ:GANX). The article does not provide a specific price target or further details on the analyst's rationale.
- Tone
- Positive 68/100
- Event
- Analyst action
- Published
- 01 Jul 2026 14:42
- Source
- Moomoo
GuruFocus
Direct company coverage
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00
HC Wainwright & Co. has reiterated its 'Buy' rating for Gain Therapeutics (GANX), maintaining a price target of $8.00, significantly higher than its current trading price of $2.03. While the company's GF Score of 32/100 indicates potential weaknesses in profitability and growth,
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 01 Jul 2026 13:39
- Source
- GuruFocus
Moomoo
Direct company coverage
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 01 Jul 2026 07:00
- Source
- Moomoo
Moomoo
Direct company coverage
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines
This article highlights several stocks for investors to watch, including AeroVironment (AVAV), Concentrix (CNXC), Gain Therapeutics (GANX), and Praxis Precision Medicines (PRAX). Each company's stock is experiencing specific market movements or has upcoming events that could impa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 13:11
- Source
- Moomoo
Moomoo
Direct company coverage
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease
Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing the company to proceed with Phase 2 clinical trials for Parkinson's disease. GT-02287 is a brain-penetrant allosteric activator of GCase, designed to address
- Tone
- Positive 70/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 12:39
- Source
- Moomoo
TradingView
Direct company coverage
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX
This article provides information on the number of shareholders for Gain Therapeutics, Inc. (NASDAQ: GANX). It is a financial data point from TradingView, which aggregates market data from various sources. The article itself does not provide the specific number of shareholders, b
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 12:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX
The article focuses on the "Price to sales forward" metric for Gain Therapeutics, Inc. (NASDAQ: GANX). It presents financial data related to this metric, indicating its value, change, and percentage change over a specified period. The information is provided by TradingView, with
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 08:10
- Source
- TradingView
Investing.com Nigeria
Direct company coverage
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 29 Jun 2026 20:43
- Source
- Investing.com Nigeria
MT Newswires
Direct company coverage
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease
- Tone
- Positive 58/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 20:36
- Source
- MT Newswires
Investing.com India
Direct company coverage
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug
Gain Therapeutics Inc. (NASDAQ:GANX) saw its shares rise significantly after the FDA cleared its Investigational New Drug application for GT-02287, a Parkinson’s disease treatment. This clearance allows the company to initiate a Phase 2 clinical trial in the U.S. in Q3 2026, foll
- Tone
- Positive 93/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 20:41
- Source
- Investing.com India
Stock Titan
Direct company coverage
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial
Gain Therapeutics (GANX) announced that the FDA has authorized its Investigational New Drug (IND) application for GT-02287. This clearance allows the company to proceed with Phase 2 clinical trials in the United States for Parkinson's disease, with or without a GBA1 mutation. The
- Tone
- Positive 70/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 20:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial
Gain Therapeutics (NASDAQ: GANX) has received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing it to proceed with Phase 2 clinical development for Parkinson's disease in the U.S. This decision follows positive Phase 1 results that showed fav
- Tone
- Positive 94/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 19:41
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX
This article provides information about the "Price to earnings forward" for Gain Therapeutics, Inc. (NASDAQ: GANX). It appears to be a financial data point available on TradingView, indicating a specific financial metric for the company. The content itself seems to be a financial
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 15:41
- Source
- TradingView
Sahm
Direct company coverage
3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research
This article highlights three clinical-stage biotech companies, Gain Therapeutics (GANX), MeiraGTx Holdings (MGTX), and Alto Neuroscience (ANRO), that are actively involved in Parkinson's research. It discusses their current clinical progress, market capitalization, revenue, and
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 25 Jun 2026 23:41
- Source
- Sahm
TradingView
Direct company coverage
Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX)
This article provides an overview of Gain Therapeutics, Inc. (NASDAQ:GANX) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and addresses common investor question
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:10
- Source
- TradingView
Stock Titan
Direct company coverage
Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting
Gain Therapeutics, Inc. held its annual stockholder meeting on June 24, 2026, where shareholders elected seven directors to one-year terms and ratified Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The director
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 20:59
- Source
- Stock Titan
TradingView
Direct company coverage
GANX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Gain Therapeutics, Inc. (GANX) stock, including analyst price targets, historical performance, and essential financial data. It highlights that five analysts have offered a 1-year price forecast, with a maximum estimate of $8.00 and a minimum
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 25 Jun 2026 17:09
- Source
- TradingView
TradingKey
Direct company coverage
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Gain Therapeutics Inc (GANX), detailing its price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 7.01 and is trading betwee
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 09:10
- Source
- TradingKey
TradingKey
Direct company coverage
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Gain Therapeutics Inc (GANX), highlighting its current earnings forecast score of 8.80 within the Biotechnology & Medical Research industry. It details analyst ratings, with a strong buy consensus and a target price of $7.00, along w
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 19 Jun 2026 20:09
- Source
- TradingKey
TradingKey
Direct company coverage
Gain Therapeutics Inc (GANX) Institutional Confidence
Gain Therapeutics Inc (GANX) has an institutional shareholding score of 3.00, ranking 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.25%, marking a 58.16% increase quarter-over-quarter. Bill Nygren | OAKMX
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 19 Jun 2026 03:10
- Source
- TradingKey